Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

NCT05927142 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

BIOLOGICAL: Durvalumab
DRUG: Rintatolimod

Sponsor

Joachim Aerts, MD PhD

Collaborators

[object Object]
[object Object]